Learning objectives: 

Generalized pustular psoriasis (GPP) is defined as a chronic, heterogeneous, neutrophilic, inflammatory disease according to the European Rare and Severe Psoriasis Expert Network (ERASPEN) Guidelines, Japanese Dermatological Association (JDA) Guidelines, Global Delphi Consensus, and National Psoriasis Foundation Consensus of GPP. In the phases of post-flare/in-between, 86% of GPP patients have chronic symptoms, and reported a poor quality of life (QoL) and feelings of fear and anxiety. Following initial treatment for GPP flares, 83% of the patients still had chronic symptoms, including skin scaling, skin lesions, and erythema. The chronicity of GPP has created a heavy burden in the patients. Hence, the expert panel of the Global Delphi Consensus has concluded the treatment goals of rapid and sustained clearance of pustules, erythema, scaling and crust, clearance of skin lesions and prevention of new flares.

Although the evidence for guiding GPP treatment has remained scarce, there are updates in evidence for a new treatment option recently.

 Prof. Henry Chan will review the updated evidence and treatment guideline in the acute flare and long-term management of GPP. A GPP Workshop featuring a virtual reality experience will precede the lecture.